7/31/2013

GE Healthcare said the final module of its premarket approval application for the GE Breast Tomosynthesis system has been forwarded to the FDA. The technology, which serves as an add-on option for the company's Senographe Essential device, delivers 3D digital images of the breast to aid in the detection of breast cancer.

Related Summaries